[go: up one dir, main page]

WO2003032913A3 - Methods and compositions for targeting proteins across the blood brain barrier - Google Patents

Methods and compositions for targeting proteins across the blood brain barrier Download PDF

Info

Publication number
WO2003032913A3
WO2003032913A3 PCT/US2002/032996 US0232996W WO03032913A3 WO 2003032913 A3 WO2003032913 A3 WO 2003032913A3 US 0232996 W US0232996 W US 0232996W WO 03032913 A3 WO03032913 A3 WO 03032913A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
brain
igf
brain barrier
Prior art date
Application number
PCT/US2002/032996
Other languages
French (fr)
Other versions
WO2003032913A9 (en
WO2003032913A2 (en
Inventor
Jonathan H Lebowitz
Original Assignee
Symbiontics Inc
Jonathan H Lebowitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/136,841 external-priority patent/US7396811B2/en
Priority claimed from US10/136,639 external-priority patent/US20030072761A1/en
Application filed by Symbiontics Inc, Jonathan H Lebowitz filed Critical Symbiontics Inc
Priority to AU2002347910A priority Critical patent/AU2002347910A1/en
Publication of WO2003032913A2 publication Critical patent/WO2003032913A2/en
Publication of WO2003032913A9 publication Critical patent/WO2003032913A9/en
Publication of WO2003032913A3 publication Critical patent/WO2003032913A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)

Abstract

Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural tissue in the brain from blood. Methods and compositions of the invention include therapeutic applications for treating lysosomal storage diseases. The invention also provides nucleic acids and cells for expressing IGF fusion proteins.
PCT/US2002/032996 2001-10-16 2002-10-16 Methods and compositions for targeting proteins across the blood brain barrier WO2003032913A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002347910A AU2002347910A1 (en) 2001-10-16 2002-10-16 Methods and compositions for targeting proteins across the blood brain barrier

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32965001P 2001-10-16 2001-10-16
US60/329,650 2001-10-16
US10/136,841 US7396811B2 (en) 2001-04-30 2002-04-30 Subcellular targeting of therapeutic proteins
US10/136,639 2002-04-30
US10/136,639 US20030072761A1 (en) 2001-10-16 2002-04-30 Methods and compositions for targeting proteins across the blood brain barrier
US10/136,841 2002-04-30
US38445202P 2002-05-29 2002-05-29
US60/384,452 2002-05-29
US38601902P 2002-06-05 2002-06-05
US60/386,019 2002-06-05
US40881602P 2002-09-06 2002-09-06
US60/408,816 2002-09-06

Publications (3)

Publication Number Publication Date
WO2003032913A2 WO2003032913A2 (en) 2003-04-24
WO2003032913A9 WO2003032913A9 (en) 2004-04-29
WO2003032913A3 true WO2003032913A3 (en) 2004-08-12

Family

ID=27558195

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/032996 WO2003032913A2 (en) 2001-10-16 2002-10-16 Methods and compositions for targeting proteins across the blood brain barrier
PCT/US2002/032968 WO2003032727A1 (en) 2001-10-16 2002-10-16 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032968 WO2003032727A1 (en) 2001-10-16 2002-10-16 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier

Country Status (6)

Country Link
EP (1) EP1446007A4 (en)
JP (2) JP2005506340A (en)
AU (3) AU2002347910A1 (en)
CA (1) CA2463473A1 (en)
IL (1) IL161352A0 (en)
WO (2) WO2003032913A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (en) 2001-04-30 2008-02-15 Zystor Therapeutics Inc SUB-CELLULAR TARGETING OF THERAPEUTIC PROTEINS
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP1446007A4 (en) * 2001-10-16 2005-12-07 Zystor Therapeutics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
AU2003237314B2 (en) * 2002-05-29 2010-03-04 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
JP4914224B2 (en) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド Acid α-glucosidase and its fragments
CA3184105A1 (en) 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
PT2234600E (en) * 2007-12-21 2014-09-25 Hoffmann La Roche Antibody formulation
BR122017015900A2 (en) 2008-05-07 2019-09-10 Biomarin Pharm Inc nucleic acid and cells
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP4273164A3 (en) 2009-10-09 2024-01-24 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
CN103282046B (en) 2010-06-25 2015-05-13 夏尔人类遗传性治疗公司 Methods and compositions for CNS delivery of arylsulfatase A
HUE052944T2 (en) 2010-06-25 2021-05-28 Shire Human Genetic Therapies Cns delivery of therapeutic agents
NZ605871A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
IL291554B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Cns delivery of therapeutic agents
KR102356192B1 (en) 2010-06-25 2022-02-08 샤이어 휴먼 지네틱 테라피즈 인크. Methods and compositions for cns delivery of iduronate-2-sulfatase
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
HK1204002A1 (en) * 2011-12-01 2015-11-06 Angiochem Inc. Targeted lysosomal enzyme compounds
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MX367024B (en) 2012-11-27 2019-08-02 Biomarin Pharm Inc Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof.
EP2968535A2 (en) * 2013-03-15 2016-01-20 Glaxosmithkline Intellectual Property (No. 2) Limited Low concentration antibody formulations
RU2708026C2 (en) 2014-04-01 2019-12-03 Свидиш Орфан Биовитрум Аб (Пабл) Modified sulphamidase and method for production thereof
JP6823055B2 (en) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド How to treat soft meningeal carcinomatosis
EP4275751A3 (en) 2016-02-24 2023-12-27 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
JP2021521851A (en) 2018-04-30 2021-08-30 アミカス セラピューティックス インコーポレイテッド Gene therapy constructs and usage
KR102743734B1 (en) 2018-10-10 2024-12-17 아미쿠스 세라퓨틱스, 인코포레이티드 Disulfide bond stabilized polypeptide composition and method of use
WO2020132452A1 (en) 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
WO1991004014A1 (en) * 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
ATE384736T1 (en) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc SUB-CELLULAR TARGETING OF THERAPEUTIC PROTEINS
EP1446007A4 (en) * 2001-10-16 2005-12-07 Zystor Therapeutics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
AU2003237314B2 (en) * 2002-05-29 2010-03-04 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Also Published As

Publication number Publication date
EP1446007A4 (en) 2005-12-07
AU2002347910A1 (en) 2003-04-28
EP1446007A1 (en) 2004-08-18
CA2463473A1 (en) 2003-04-24
JP2009203241A (en) 2009-09-10
WO2003032727A1 (en) 2003-04-24
JP2005506340A (en) 2005-03-03
AU2010214643A1 (en) 2010-09-16
IL161352A0 (en) 2004-09-27
AU2002362930A2 (en) 2003-04-28
WO2003032913A9 (en) 2004-04-29
WO2003032913A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
WO2003032913A3 (en) Methods and compositions for targeting proteins across the blood brain barrier
EP1362917A3 (en) A fusion protein for use as vector
WO2004047863A3 (en) Genetic products differentially expressed in tumors and the use thereof
MY154826A (en) Fusion protein capable of binding vegf
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
WO2006007560A3 (en) Targeted protein replacement for the treatment of lysosomal storage disorders
WO2002064766A3 (en) Bax-responsive genes for drug target identification in yeast and fungi
EP0744408A3 (en) Rhesus ob protein and DNA
EP0772625A4 (en) OLIGONUCLEOSIDES AND METHOD FOR INHIBITING TUMOR GROWTH, INVASION AND METASTASIS
WO2004087766A3 (en) Peptabody for cancer treatment
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO2024147897A3 (en) Trop2 targeting trispecific protein for treatment of cancer
WO2001054707A3 (en) Modification of surface proteins by aminopeptidase inhibitors
WO2003003977A3 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2001002550A3 (en) Cell death related drug targets in yeast and fungi
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003018829A3 (en) 6299, a human zinc carboxypeptidase family member and uses therefor
WO2001079473A3 (en) 21953, a human prolyl oligopeptidase family member and uses thereof
WO2003083037A3 (en) Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
WO2001070948A3 (en) Methods and compositions for elucidating protein expression profiles in cells
WO2004049917A3 (en) Methods of therapy and diagnosis using targeting of cells that express ly-9
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP